---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002784"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:31:12.060598+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics Q1 net loss $10.8M; cash $156.3M; FDA Fast Track for CTX-009

## Summary
- Net loss $10.8M ($0.08/share) vs $7.8M ($0.06) in Q1 2023; R&D expenses rose to $9.5M.
- Cash and marketable securities $156.3M at March 31, 2024; cash runway into late 2026.
- FDA Fast Track for CTX-009 in BTC; COMPANION-002 enrollment to complete mid-2024, data Q1 2025.
- Stage 1 of COMPANION-003 (CRC) enrollment complete; top-line data expected by mid-2024.
- CTX-8371 first patient dosed in April 2024; Phase 2 planned for CTX-471 in melanoma with biomarker.

## SEC filing metadata
- accession: 0001171843-24-002784
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184324002784/0001171843-24-002784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184324002784/f8k_051124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002784
- JSON: https://secwatch.observer/filing/0001171843-24-002784.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002784.txt

## Key facts
- Earnings Releases
  Compass Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $10.8 million, EPS $0.08 per share of common stock.
  - Period: the quarter ended March 31, 2024
  - Net income: $10.8 million
  - EPS: $0.08 per share of common stock
  - Result: reported results
  source text: On May 13, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184324002784/0001171843-24-002784-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.